Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

WHAT'S NEW

  • Vaccine Policy in Colorado
  • Family Separation
  • Shakeup at U.S. Preventive Services Task Force
  • Ebola
  • ACA Enrollment

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Monday, Apr 14 2025

Full Issue

Viewpoints: Let's Keep Realistic CRISPR Expectations; 'Most Favored Nation' Drug Pricing Falls Short

Opinion writers discuss these public health topics.

Stat: Biotech Investors: Stop Expecting CRISPR Science To Make Big Leaps 

CRISPR is not a miracle product that can magically cure cancer. It is, however, an exceptionally powerful tool that is creating entirely new possibilities in cancer treatment. (Kelly Banas and Eric B. Kmiec, 4/14)

Stat: 'Most-Favored Nation' Drug Pricing Has Three Significant Problems

The administration is exploring so-called “most-favored nation” (MFN) pricing, which pegs U.S. drug prices to the lowest level paid by comparable countries. At the end of his first term, President Trump ordered Medicare to implement such an MFN policy, only to have the order blocked by the Biden administration. (Darius Lakdawalla and Dana P. Goldman, 4/14)

Bloomberg: RFK Jr. Needs To Explain How He'll Protect Americans Amid HHS Cuts 

Some 10,000 federal health workers lost their jobs earlier this month — among them, a group of regulators who help new medicines get approved. If Health and Human Services Secretary Robert F. Kennedy Jr. doesn’t reverse course, American patients will suffer and half a century of US leadership in pharmaceutical innovation could come to a precipitous end. (4/14)

The Washington Post: The Trump-Kennedy Cuts At NIH Will Crush Our Leadership In Biomedicine

When Donald Trump accepted the 2024 GOP nomination for president, he included in his speech the importance of American leadership in biomedical innovation. “We’re going to get to the cure for cancer and Alzheimer’s and so many other things,” he said. “We’re so close to doing something great. But we need a leader that will let it be done.” (Fred Upton and Diana DeGette, 4/14)

The New York Times: What Is Actually The Point Of Treating The N.I.H. Like This? 

By the time their spending accounts were reactivated on Thursday, some scientists at the National Institutes of Health said they were running on fumes. (Jeneen Interlani, 4/11)

The CT Mirror: A Parent's Worst Nightmare: RSV

According to the CDC, RSV is the leading cause of infant hospitalization in the U.S. It’s estimated that 58,000-80,000 children younger than five years old are hospitalized each year due to RSV. What’s so scary about RSV is that babies and kids are dying from this virus. (Sophia Bechenek, 4/14)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, May 22
  • Thursday, May 21
  • Wednesday, May 20
  • Tuesday, May 19
  • Monday, May 18
  • Friday, May 15
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF